ResearcherWashington University in St. LouisActive in the last 2 years
Sapana Bansod
Matched on ORCID iD 0000-0002-9818-3575; OpenAlex author ID A5024072274. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers
Papers 6
- Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.04.017↗
- Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic. Co-author DOI 10.1186/s12943-026-02597-7↗
- Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade Co-author DOI 10.1101/2025.10.08.681226↗
- Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. Co-author DOI 10.1038/s41467-024-46811-w↗
- A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy. Co-author DOI 10.1158/1078-0432.ccr-23-1405↗
- Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities. Co-author DOI 10.3390/cancers13215481↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kian‐Huat Lim · 5 shared papers, 2021–2026 · strength 1.04
- Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
- Paper Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade DOI 10.1101/2025.10.08.681226↗
- Paper Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunit… DOI 10.3390/cancers13215481↗
- Vikas Somani · 4 shared papers, 2024–2026 · strength 0.90
- Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
- Paper Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade DOI 10.1101/2025.10.08.681226↗
- Paper Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanothe… DOI 10.1186/s12943-026-02597-7↗
- David G DeNardo · 4 shared papers, 2024–2026 · strength 0.90
- Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
- Paper Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade DOI 10.1101/2025.10.08.681226↗
- Paper Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanothe… DOI 10.1186/s12943-026-02597-7↗
- Ryan C Fields · 3 shared papers, 2024–2026 · strength 0.66
- Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
- Paper Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockade DOI 10.1101/2025.10.08.681226↗
- Paper Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. DOI 10.1038/s41467-024-46811-w↗
- Ashenafi Shiferaw Bulle · 3 shared papers, 2024–2026 · strength 0.65
- Paper Blockade of Tumor TAK1 Induces DNA Damage and Immunogenic cGAS-STING Pathway Activation in Pancreatic Cancer. DOI 10.1053/j.gastro.2026.04.017↗
- Paper Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanothe… DOI 10.1186/s12943-026-02597-7↗
- Paper Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. DOI 10.1038/s41467-024-46811-w↗
- Paarth B. Dodhiawala · 2 shared papers, 2021–2024 · strength 0.37
- Paper Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunit… DOI 10.3390/cancers13215481↗
- Paper Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. DOI 10.1038/s41467-024-46811-w↗
- Patrick M. Grierson · 2 shared papers, 2023–2024 · strength 0.31
- Paper A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Pr… DOI 10.1158/1078-0432.ccr-23-1405↗
- Paper Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. DOI 10.1038/s41467-024-46811-w↗
- Andrea Wang‐Gillam · 2 shared papers, 2023–2024 · strength 0.31
- Paper A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Pr… DOI 10.1158/1078-0432.ccr-23-1405↗
- Paper Combined KRAS-MAPK pathway inhibitors and HER2-directed drug conjugate is efficacious in pancreatic cancer. DOI 10.1038/s41467-024-46811-w↗
- Liang‐I Kang · 1 shared paper, 2026 · strength 0.24
- Kian-Huat Lim · 1 shared paper, 2026 · strength 0.24
- Benjamin R. Tan · 1 shared paper, 2023 · strength 0.16
- Katrina Sophia Pedersen · 1 shared paper, 2023 · strength 0.16
- William G. Hawkins · 1 shared paper, 2024 · strength 0.15
- Ramaswamy Govindan Md · 1 shared paper, 2024 · strength 0.15
- Li Ding · 1 shared paper, 2024 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.